Subconjunctival mitomycin C as adjunctive therapy before pterygium excision.
OBJECTIVE
To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery.


METHODS
Prospective noncomparative case series.


METHODS
Thirty-six eyes of 36 patients.


METHODS
Thirty-six eyes of 36 patients prospectively received 0.1 ml of 0.15 mg/ml mitomycin C subconjunctivally injected into the head of the pterygium 1 month before bare sclera surgical excision.


METHODS
Recurrence of pterygia.


RESULTS
The pterygia resolved in 34 (94%) of 36 eyes, with a recurrence rate of 6% over a mean follow-up of 24.4 months. No wound-healing complication developed in any patient.


CONCLUSIONS
Subconjunctival mitomycin C is an effective treatment before pterygium excision. Subconjunctival injection allows exact titration of mitomycin C delivery to the activated fibroblasts and minimizes epithelial toxicity.
Donnenfeld
Eric D
ED
Nassau University Medical Center, East Meadow, New York, USA. eddoph@aol.com
Perry
Henry D
HD
Fromer
Susan
S
Doshi
Sima
S
Solomon
Renée
R
Biser
Seth
S
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003228:Conjunctiva; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D011300:Preoperative Care; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D012008:Recurrence; D012449:Safety; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin